Tilray | TRLY - Ebitda


Tilray reported $8.36M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acasti Pharma USD -3.01M 562K Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Aurora Cannabis CAD 3.7M 14.78M Mar/2026
Avita Medical AUD -9.69M 12.21M Dec/2025
Canopy Growth CAD -137M 134.13M Mar/2026
Cronos Group USD -1.41M 1.86M Mar/2026
Dianthus Therapeutics USD -46.46M 6.27M Mar/2026
Divis Laboratories Ltd INR 12.62B 3.28B Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
IQVIA Holdings USD 1.03B 38M Sep/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Moderna USD -1.26B 468M Mar/2026
Organigram Holdings CAD -4.76M 10.02M Mar/2026
Organon & Co USD 371M 44M Jun/2026
Revvity USD 228.18M 44.73M Jun/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1.19B 138.8M Jun/2026
Xeris Pharmaceuticals USD 12.33M 12.76M Mar/2026
Zealand Pharma A/S -379M 348.47M Mar/2026